

EFFECTIVENESS AND SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS IN CLINICAL PRACTICE: RESULTS FROM THE U-REAL-UC STUDY FROM ENEIDA

Javier P. Gisbert

UEG Week Berlin 2025

Poster

IBD

October 7, 2025

Real-world registry study of 168 ulcerative colitis patients treated with upadacitinib shows steroid-free clinical remission rates of 67-75% over 18 months, with a discontinuation rate of 27% per patient-year.

KEY POINTS

- Among 168 patients (48% previously exposed to JAK inhibitors, 31% to all approved targets), steroid-free clinical remission was achieved in 67% at week 8, 71% at week 16, 65% at month 6, 60% at month 12, and 75% at month 18.
- Prior JAK inhibitor exposure was associated with lower short-term remission rates at week 8 (OR 0.29) but did not affect treatment discontinuation rates.
- Of 13 patients who lost response after initial remission, 10 underwent dose escalation and 9 of these (90%) regained steroid-free clinical remission.
- Adverse events occurred in 27% of patients, most commonly hypercholesterolemia, with no major cardiovascular or thromboembolic events reported.
- This prospective registry study may inform clinicians managing ulcerative colitis patients with prior biologic or JAK inhibitor exposure.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/766ff846-a813-11f0-a3b1-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.